Sign In
Buy TLSA
$1.03
+0.0600 (+6.19%)
At Close: Jul 31, 2026
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease
09:15am, Tuesday, 11'th Feb 2025
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences reports promising preclinical results for nasal anti-CD3 in spinal cord injury
03:31pm, Thursday, 23'rd Jan 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced positive results from studies of a nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury (SCI). SCI represents a major global health
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
03:00pm, Thursday, 23'rd Jan 2025
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences not to engage in capital raising activities for the immediate future
08:54am, Thursday, 23'rd Jan 2025
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences identifies new immune biomarkers in MS patients treated with foralumab
04:36pm, Wednesday, 22'nd Jan 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with its novel thera
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
04:05pm, Wednesday, 22'nd Jan 2025
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences' foralumab reduces side effects of discontinuing GLP-1 agonists
10:09am, Friday, 10'th Jan 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its intranasal anti-CD3 monoclonal antibody, foralumab, has demonstrated the ability to mitigate the side effects associated with the discontinua
Tiziana Life Sciences welcomes publication of article highlighting foralumab's potential in neurological diseases
08:45am, Wednesday, 08'th Jan 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the publication of a review article in Nature Reviews Neurology that examines the potential of its lead therapeutic candidate intranasal foralumab
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences doses first Alzheimer's patient with intranasal foralumab
09:13am, Tuesday, 17'th Dec 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has dosed the first patient with moderate Alzheimer's disease with its lead investigational drug candidate intranasal foralumab. The company
Tiziana Life Sciences expands Phase 2 MS trial to additional top US medical institutions
08:38am, Wednesday, 04'th Dec 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has expanded its Phase 2 clinical trial evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis (SPMS) to addi
Tiziana Life Sciences secures grant for ALS trial
08:47am, Tuesday, 19'th Nov 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its grant application to the ALS Association has been approved. The company has secured funding under the Hoffman ALS Clinical Trial Awards Progr
Tiziana Life Sciences CEO discusses foralumab potential to enhance Ozempic - ICYMI
08:18am, Saturday, 02'nd Nov 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) this week announced positive research findings showing the anti-inflammatory potential of the company's nasal anti-CD3 antibody foralumab when used in combinati
Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference
04:31pm, Friday, 01'st Nov 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm. The event will allow Tiziana to engage with industry leaders, potential collab
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
